VYGR

Voyager Therapeutics, Inc. NASDAQ Listed Nov 11, 2015

Healthcare ·Biotechnology ·US · voyagertherapeutics.com

$3.96

Mkt Cap $239.1M

52w Low $2.65 45.3% of range 52w High $5.55

50d MA $4.03 200d MA $4.04

P/E (TTM) -1.8x

EV/EBITDA -1.6x

P/B 1.1x

Debt/Equity 0.2x

ROE -61.1%

P/FCF -1.7x

RSI (14) —

ATR (14) —

Beta 1.38

50d MA $4.03

200d MA $4.04

Avg Volume 675.2K

About

Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's …

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 9, 2026	AMC	-0.54	-0.46	+14.8%	4.11	+0.0%	+21.7%	+18.0%	+18.5%	+8.5%	+5.1%	—
Nov 10, 2025	AMC	-0.53	-0.47	+11.3%	4.26	-0.5%	+0.0%	-0.2%	-6.6%	-7.7%	-3.5%	—
Aug 6, 2025	AMC	-0.48	-0.57	-18.8%	3.40	+0.0%	-5.3%	-7.6%	-9.4%	-0.3%	+7.4%	—
May 6, 2025	AMC	-0.35	-0.53	-51.4%	3.25	-0.3%	+0.9%	+5.5%	-2.5%	+3.1%	+0.9%	—
Mar 11, 2025	AMC	-0.35	-0.59	-68.6%	3.97	-4.3%	+2.3%	+2.5%	-1.8%	-2.0%	-2.0%	—
Nov 12, 2024	AMC	-0.45	-0.16	+64.4%	6.83	+2.8%	-2.0%	-8.9%	-17.4%	-21.1%	-22.8%	—
Aug 6, 2024	AMC	-0.38	-0.18	+52.6%	8.19	+4.2%	-14.0%	-11.4%	-15.5%	-19.0%	-19.4%	—
May 13, 2024	AMC	-0.44	-0.20	+54.5%	8.48	+1.8%	+0.0%	+1.1%	+1.8%	-0.6%	-0.4%	—
Feb 28, 2024	AMC	-0.29	1.25	+531.0%	8.97	+10.8%	-7.2%	+5.2%	+7.5%	+1.4%	+2.9%	—
Nov 6, 2023	AMC	-0.58	-0.59	-1.7%	6.49	-2.0%	+5.1%	+4.9%	-1.7%	-2.2%	-3.2%	—
Aug 3, 2023	AMC	-0.59	-0.51	+13.6%	9.31	+0.9%	-4.9%	-6.8%	-4.5%	-2.8%	-1.9%	—
May 9, 2023	AMC	0.77	2.94	+281.8%	10.76	+0.1%	-8.1%	-8.2%	-3.0%	-3.3%	+5.6%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Mar 17	HC Wainwright & Co.	Maintains	Buy → Buy	—	$4.32	$4.33	+0.2%	-9.3%	-13.0%	-13.4%	-10.9%	-10.2%
Nov 12	HC Wainwright & Co.	Maintains	Buy → Buy	—	$4.26	$4.30	+0.9%	-0.2%	-6.6%	-7.7%	-3.5%	+0.5%
Sep 15	HC Wainwright & Co.	Maintains	Buy → Buy	—	$4.18	$4.18	+0.0%	+0.7%	+1.7%	+1.9%	+7.4%	+2.2%
Aug 7	Wedbush	Maintains	Outperform → Outperform	—	$3.40	$3.40	+0.0%	-5.3%	-7.6%	-9.4%	-0.3%	+7.4%
Apr 8	HC Wainwright & Co.	Maintains	Buy → Buy	—	$3.06	$3.17	+3.6%	-6.9%	+1.6%	-2.3%	+3.6%	+4.2%
Mar 13	HC Wainwright & Co.	Maintains	Buy → Buy	—	$4.06	$4.10	+1.0%	+0.2%	-3.9%	-4.2%	-4.2%	+0.7%
Mar 13	Canaccord Genuity	Maintains	Buy → Buy	—	$4.06	$4.10	+1.0%	+0.2%	-3.9%	-4.2%	-4.2%	+0.7%
Mar 12	Wells Fargo	Maintains	Overweight → Overweight	—	$3.97	$3.80	-4.3%	+2.3%	+2.5%	-1.8%	-2.0%	-2.0%
Mar 12	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$3.97	$3.80	-4.3%	+2.3%	+2.5%	-1.8%	-2.0%	-2.0%
Mar 12	Wedbush	Maintains	Outperform → Outperform	—	$3.97	$3.80	-4.3%	+2.3%	+2.5%	-1.8%	-2.0%	-2.0%
Mar 3	HC Wainwright & Co.	Maintains	Buy → Buy	—	$4.08	$4.13	+1.2%	-4.2%	-2.9%	+1.7%	+1.5%	+4.4%
Jan 27	HC Wainwright & Co.	Maintains	Buy → Buy	—	$5.62	$5.60	-0.4%	+0.2%	-0.4%	-1.8%	-0.2%	-3.0%
Nov 14	Canaccord Genuity	Maintains	Buy → Buy	—	$6.69	$6.73	+0.6%	-7.0%	-15.7%	-19.4%	-21.2%	-19.9%
Nov 14	HC Wainwright & Co.	Maintains	Buy → Buy	—	$6.69	$6.73	+0.6%	-7.0%	-15.7%	-19.4%	-21.2%	-19.9%
Oct 24	HC Wainwright & Co.	Maintains	Buy → Buy	—	$6.43	$6.44	+0.2%	+2.3%	+5.0%	+9.2%	+10.0%	+6.4%
Aug 20	HC Wainwright & Co.	Maintains	Buy → Buy	—	$6.66	$6.75	+1.4%	+4.4%	+3.2%	+0.2%	+2.1%	+3.3%
Aug 7	Wedbush	Maintains	Neutral → Neutral	—	$8.19	$8.53	+4.2%	-14.0%	-11.4%	-15.5%	-19.0%	-19.4%
Jul 31	HC Wainwright & Co.	Maintains	Buy → Buy	—	$9.26	$9.27	+0.1%	-0.8%	-6.3%	-10.4%	-13.9%	-11.6%
May 16	HC Wainwright & Co.	Maintains	Buy → Buy	—	$8.57	$8.65	+0.9%	+0.7%	-1.6%	-1.4%	-1.5%	-3.2%
May 15	Oppenheimer	Maintains	Outperform → Outperform	—	$8.48	$8.52	+0.5%	+1.1%	+1.8%	-0.6%	-0.4%	-0.5%
May 14	Wedbush	Maintains	Neutral → Neutral	—	$8.48	$8.63	+1.8%	+0.0%	+1.1%	+1.8%	-0.6%	-0.4%
Jan 2	Wells Fargo	Upgrade	Equal Weight → Overweight	—	$8.44	$10.53	+24.8%	+6.6%	+27.6%	+28.4%	+4.9%	+7.3%
Aug 7	Oppenheimer	Maintains	Outperform → Outperform	—	$8.85	$8.77	-1.0%	-1.9%	+0.5%	+2.3%	+3.2%	+5.5%
May 10	Canaccord Genuity	Maintains	Buy → Buy	—	$10.76	$10.77	+0.1%	-8.1%	-8.2%	-3.0%	-3.3%	+5.6%
May 10	Truist	Maintains	Buy → Buy	—	$10.76	$10.77	+0.1%	-8.1%	-8.2%	-3.0%	-3.3%	+5.6%
Mar 10	Oppenheimer	Maintains	Outperform → Outperform	—	$7.91	$8.25	+4.3%	-4.9%	-0.5%	+4.8%	+1.4%	+3.8%
Nov 3	Chardan Capital	Maintains	Neutral → Neutral	—	$3.89	$3.89	+0.0%	+2.6%	-2.8%	-2.3%	-6.2%	-7.2%
Oct 7	Baird	Upgrade	Neutral → Outperform	—	$3.87	$3.94	+1.8%	-0.8%	+43.4%	+24.0%	+19.1%	+17.1%
Apr 19	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$4.56	$4.56	+0.0%	-2.0%	+2.4%	+5.0%	+3.1%	+2.4%
Feb 26	Baird	Downgrade	Outperform → Neutral	—	$6.23	$5.90	-5.3%	-9.0%	-4.2%	-9.0%	-11.1%	-10.4%
Feb 3	BTIG	Downgrade	Buy → Neutral	—	$8.00	$7.00	-12.5%	-6.4%	-6.6%	-6.9%	-3.8%	-5.8%
Feb 3	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$8.00	$7.00	-12.5%	-6.4%	-6.6%	-6.9%	-3.8%	-5.8%
Feb 3	Wedbush	Downgrade	Outperform → Neutral	—	$8.00	$7.00	-12.5%	-6.4%	-6.6%	-6.9%	-3.8%	-5.8%
Nov 11	Oppenheimer	Downgrade	Outperform → Perform	—	$8.60	$8.71	+1.3%	+2.9%	+0.3%	-0.6%	+1.6%	+1.3%
Nov 10	Raymond James	Downgrade	Strong Buy → Outperform	—	$11.20	$10.01	-10.6%	-23.2%	-21.0%	-22.9%	-23.7%	-22.0%
Nov 10	Wells Fargo	Downgrade	Overweight → Equal Weight	—	$11.20	$10.01	-10.6%	-23.2%	-21.0%	-22.9%	-23.7%	-22.0%
Aug 4	HC Wainwright & Co.	Maintains	Buy → Buy	—	$11.33	$10.83	-4.4%	-8.6%	-4.6%	-3.0%	-1.2%	-1.3%
Apr 15	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$10.25	$9.72	-5.2%	-6.2%	-6.5%	-0.5%	+1.6%	+2.3%
Mar 30	Nomura	Maintains	Buy → Buy	—	$9.05	$9.11	+0.7%	-3.3%	+1.1%	-11.0%	-3.9%	-10.2%
Mar 19	Benchmark	Maintains	Buy → Buy	—	$7.16	$7.26	+1.4%	+5.6%	-3.6%	+0.8%	+19.1%	+28.8%
Mar 4	HC Wainwright & Co.	Maintains	Buy → Buy	—	$11.58	$12.31	+6.3%	+4.3%	+0.6%	-5.3%	-11.8%	-6.1%
Mar 4	Wedbush	Maintains	Outperform → Outperform	—	$11.58	$12.31	+6.3%	+4.3%	+0.6%	-5.3%	-11.8%	-6.1%
Mar 4	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$11.58	$12.31	+6.3%	+4.3%	+0.6%	-5.3%	-11.8%	-6.1%
Feb 6	Oppenheimer	Maintains	Outperform → Outperform	—	$12.66	$13.10	+3.5%	+7.6%	+2.4%	+2.4%	+4.3%	+6.8%
Oct 11	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$14.93	$15.10	+1.1%	+1.5%	-0.3%	+3.1%	+1.6%	+3.2%
Jul 12	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$25.67	$26.02	+1.4%	-0.7%	-0.1%	-3.6%	-6.7%	-4.4%
Mar 6	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$17.76	$17.99	+1.3%	-5.3%	-2.5%	-2.5%	+4.6%	-1.4%
Nov 15	Raymond James	Upgrade	Outperform → Strong Buy	—	$11.25	$12.43	+10.5%	+8.3%	+10.7%	+3.0%	+3.2%	+5.4%
Nov 8	Baird	Maintains	Outperform → Outperform	—	$13.99	$11.20	-19.9%	-12.0%	-11.9%	-17.7%	-15.7%	-19.6%
Jun 4	H.C. Wainwright	Maintains	Buy → Buy	—	$20.41	$22.27	+9.1%	+3.6%	+6.1%	+10.2%	+10.2%	+9.6%

Recent Filings

8-K · 5.02 !!! Very High

Voyager Therapeutics, Inc. -- 8-K 5.02: Executive Change

Voyager Therapeutics replaced CFO Nathan Jorgensen while elevating Robin Swartz to COO and adding Amy Quinlan as director, signaling operational restructuring effective May 2026.

Apr 21

8-K

Voyager Therapeutics, Inc. -- 8-K Filing

Voyager Therapeutics expects 2026 to deliver pivotal data on tau-targeting Alzheimer's treatments, initiate clinical trials for IV-delivered gene therapies, and advance its nonviral delivery platform.

Mar 9

8-K

Voyager Therapeutics, Inc. -- 8-K Filing

Voyager Therapeutics disclosed SEC filing details regarding its emerging growth company status, which may affect regulatory reporting requirements and compliance obligations for investors.

Feb 12

Data updated apr 27, 2026 8:34am · Source: massive.com